Pendulum Therapeutics

Pendulum Therapeutics, originally known as Whole Biome Inc, was founded with the mission to improve health through innovative microbiome-based diagnostics and therapeutics. The company focuses on developing products that target the human microbiome to enhance patient care. Their flagship product, GLP-1 Probiotic, is designed to naturally increase GLP-1, a hormone that helps curb cravings and appetite, thereby aiding in weight management. Pendulum Therapeutics aims to address various health issues by leveraging beneficial bacterial strains to create effective probiotic solutions.

Notable figures affiliated with Pendulum Therapeutics include its founders and key investors from the biotechnology and healthcare sectors. The company has achieved significant milestones, including the successful development and commercialization of their GLP-1 Probiotic. Their impact is evident in the growing market for microbiome-based health products, where they have established themselves as a leader. Pendulum Therapeutics continues to advance the field of microbiome science, contributing to better health outcomes through their innovative approach.